Oncology Companion Diagnostics Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

Oncology companion diagnostics are in vitro diagnostic tests that identify patients most likely to benefit from or be harmed by a particular targeted therapy, serving as a prerequisite for the prescription of many precision oncology drugs. The market encompasses assays across multiple technology platforms, including immunohistochemistry, fluorescence in situ hybridization, quantitative polymerase chain reaction, and next-generation sequencing, with applications spanning solid tumors and hematological malignancies. With a 2026 market valuation near $8.3 billion and a growth rate of approximately 12.7% annually, the sector has expanded rapidly from estimated values around $5 billion in 2024, reflecting intensifying clinical and commercial momentum.

• •Market valued at approximately $8.3 billion in 2026, up from roughly $5.1-5.9 billion in prior years
• •Encompasses IHC, FISH, PCR, and NGS-based tests linked to targeted oncology therapies
• •Serves as a regulatory and clinical prerequisite for many precision cancer drugs

The increasing number of targeted and immuno-oncology therapies approved with companion diagnostic requirements is a primary catalyst, as regulatory agencies increasingly mandate or encourage biomarker testing to guide drug labeling and patient selection. Advances in molecular profiling technologies, particularly the declining cost of next-generation sequencing, are expanding the scope of actionable biomarkers and enabling broader multi-gene panel-based testing. Reimbursement improvements, cancer screening initiatives, and the rising global incidence of cancer across aging populations further reinforce demand for companion diagnostic testing.

• •Growing oncology drug pipeline with companion diagnostic co-development requirements
• •Declining costs of genomic sequencing enabling broader biomarker coverage
• •Regulatory and payer support for biomarker-driven precision medicine frameworks

The market is segmented by technology type, including polymerase chain reaction which holds the largest share due to its established clinical validation and cost-effectiveness, alongside immunohistochemistry, in-situ hybridization, and next-generation sequencing which is the fastest-growing segment. By cancer type, lung, breast, and colorectal cancers dominate, while the hematological malignancies segment is expanding with the advent of targeted therapies for leukemias and lymphomas. Geographically, North America leads due to advanced healthcare infrastructure, high cancer prevalence, and favorable reimbursement policies, while Europe and the Asia-Pacific region represent significant and accelerating growth markets driven by expanding diagnostic capabilities and increasing adoption of precision oncology.

• •PCR and IHC dominate by technology; NGS is the fastest-growing platform
• •Lung, breast, and colorectal cancers represent the largest application segments
• •North America leads market share; Asia-Pacific is the fastest-expanding regional market

Who are the notable companies in the industry?

The market exhibits moderate to high consolidation, with a tiered competitive structure dominated by a small number of large vertically integrated firms that span pharmaceutical partnerships, assay development, and laboratory services, alongside a broader field of mid-sized and specialty producers focused on molecular diagnostics and specific technology platforms. The primary process routes rely on in-situ hybridization and polymerase chain reaction chemistry for validated single-biomarker companion assays, with a growing shift toward comprehensive next-generation sequencing panels that integrate multiple biomarkers into a single clinical workflow. Production capacity and R&D activity are concentrated in North America and Western Europe, with Asia-Pacific emerging as a secondary hub as regional regulatory frameworks for precision medicine mature and local diagnostic manufacturers scale operations.

• •Moderately consolidated structure with dominant integrated players and a tier of specialty molecular diagnostic producers
• •Core assay technologies center on IHC, FISH, and PCR, with NGS multi-gene panels representing the fastest-growing platform segment
• •R&D and manufacturing capacity concentrated in North America and Western Europe; Asia-Pacific capacity expanding

What are the recent trends and outlook?

The market is expected to reach approximately $13.4 billion by 2035, supported by continued expansion of precision oncology drug development and the integration of companion diagnostics into earlier-line and front-line cancer treatment protocols. Emerging trends include the transition from single-biomarker companion tests to comprehensive multi-omic profiling panels, the use of liquid biopsy technology for non-invasive companion testing, and the application of artificial intelligence in biomarker discovery and assay interpretation. Regulatory harmonization of companion diagnostic approval pathways and the growth of decentralized testing models through point-of-care and laboratory-developed tests are anticipated to further accelerate market accessibility and geographic reach.

• •Market projected near $13.4 billion by 2035, underpinned by growing precision oncology pipelines
• •Multi-gene NGS panels and liquid biopsy technologies gaining clinical adoption
• •Decentralized testing models and evolving regulatory pathways expanding global access